公开(公告)号：US11623925B2

公开(公告)日：2023-04-11

申请号：US17873966

申请日：2022-07-26

申请人： YUHAN CORPORATION

发明人： Ja-Heouk Khoo ,  Doo-Byung Lee ,  Jun-Sup Lee ,  Hyun Ju ,  Woo-Seob Shin

IPC分类号： C07D403/04 ,  C07D239/47

摘要： The present invention provides a novel process for preparing a diaminopyrimidine derivative or acid addition salt thereof having an activity as a 5-HT4 receptor agonist. And also, the present invention provides novel crystalline forms of a hydrochloride of the diaminopyrimidine derivative and processes for preparing the same.

公开(公告)号：US11560416B2

公开(公告)日：2023-01-24

申请号：US16606279

申请日：2018-04-20

申请人： YUHAN CORPORATION

发明人： Byung Hyun Choi ,  In Hwan Lim ,  Jun Young Park ,  Jin Hyoung Lee ,  Ki Hong Kim ,  Hae Yong Jo ,  Jun Hwan Kim ,  Moo Young Song ,  Jong Gyun Kim

IPC分类号： C12N15/62 ,  C12N15/09 ,  C12N5/00 ,  C07K16/46 ,  C07K19/00 ,  C07K14/605 ,  C07K14/50 ,  C12P21/02 ,  C12N15/00

摘要： A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.

公开(公告)号：US20220024918A1

公开(公告)日：2022-01-27

申请号：US17368712

申请日：2021-07-06

申请人： YUHAN CORPORATION

发明人： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Dong Hoon KIM ,  Su Bin CHOI ,  Sol PARK ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC分类号： C07D471/04 ,  C07D519/00

摘要： The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20210322428A1

公开(公告)日：2021-10-21

申请号：US17285161

申请日：2019-10-17

申请人： YUHAN CORPORATION

发明人： Seongkyu KIM ,  Deokkyu LEE ,  Soo-Won KIM ,  Jun-Mo YANG ,  Yoong-Sik PARK

IPC分类号： A61K31/5377 ,  A61K9/00 ,  A61K9/20

摘要： The present disclosure provides a pharmaceutical composition for oral administration comprising: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide (Lazertinib) or its pharmaceutically acceptable salt as an active ingredient; and a combination of microcrystalline cellulose and mannitol as a diluent.

公开(公告)号：US11091479B2

公开(公告)日：2021-08-17

申请号：US16712673

申请日：2019-12-12

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Dong Hoon Kim ,  Su Bin Choi ,  Sol Park ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC分类号： C07D471/04 ,  C07D519/00

摘要： The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20210155607A1

公开(公告)日：2021-05-27

申请号：US16633756

申请日：2018-07-25

申请人： Yuhan Corporation

发明人： Sang-Ho OH ,  Ja-Heouk KHOO ,  Jong-Chul LIM ,  Doo-Byung LEE ,  Jung-Ae LEE ,  Jun-Sup LEE ,  Hyun JU ,  Woo-Seob SHIN ,  Sang-Seol JEON

IPC分类号： C07D403/04 ,  C07D295/135

摘要： The present invention provides intermediates useful for the synthesis of an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors; and processes for preparing the same. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

公开(公告)号：US10941136B2

公开(公告)日：2021-03-09

申请号：US16096712

申请日：2017-04-26

申请人： YUHAN CORPORATION

发明人： Young-Hwan Kim ,  Tae-Dong Han ,  Dong-Hoon Kim ,  Eun-Hye Jung ,  Su-Bin Choi ,  Eui-Chul Lee ,  Won-Ee Chong ,  Jin-Hwi Park ,  Jun-Chul Park ,  Ho-Woong Kang ,  Ji-Yeong Gal ,  Chan-Sun Park ,  Jong-Gyun Kim ,  Su-Youn Nam

IPC分类号： C07D239/91 ,  C07D403/14 ,  C07D217/24 ,  A61K31/51 ,  A61K31/506 ,  C07D403/12

摘要： The present invention provides a quinazoline derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The quinazoline derivative or its pharmaceutically acceptable salt has a selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit, and therefore can be usefully applied for preventing or treating cancer, along with avoiding side effects such as lymphopenia-associated inflammatory responses.

公开(公告)号：US20210024638A1

公开(公告)日：2021-01-28

申请号：US16939472

申请日：2020-07-27

申请人： ABL Bio Inc. ,  YUHAN CORPORATION

发明人： Yeryoung Yong ,  Ui-Jung Jung ,  Hyejin Chung ,  Kyeongsu Park ,  Wonjun Son ,  Yangsoon Lee ,  Yeunju Kim ,  Eunsil Sung ,  Youngkwang Kim ,  Youngdon Pak ,  Minji Park ,  Jaehyun Eom ,  Hyoju Choi ,  Moo Young Song ,  Na Rae Lee ,  Young Bong Park ,  Eun-Jung Lee ,  Eun-Jung Lee

IPC分类号： C07K16/28 ,  A61P35/00

摘要： Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US10562865B2

公开(公告)日：2020-02-18

申请号：US16359984

申请日：2019-03-20

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Dong Hoon Kim ,  Sol Park ,  Eun Hye Jung ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D249/12 ,  C07D403/10 ,  C07D403/14 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14 ,  C07D249/08 ,  C07D403/04 ,  C07D417/04 ,  C07D407/14 ,  C07D401/10 ,  C07D405/14 ,  C07D413/14

摘要： The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US09493478B2

公开(公告)日：2016-11-15

申请号：US14416079

申请日：2013-07-23

申请人： YUHAN CORPORATION

发明人： Hyoung Sig Seo ,  Tae Kyun Kim ,  Hyun Joo Lee ,  Dong Hoon Kim ,  Gyu Jin Lee ,  Jun Chul Park ,  Ji Yeong Gal ,  Tae-hoon Kim ,  Kwan Hoon Hyun ,  Kyoung Kyu Ahn ,  Kaapjoo Park ,  Su Youn Nam ,  Ge Hyeong Lee ,  Hee Jong Lim

IPC分类号： C07D491/048

CPC分类号： C07D491/048

摘要： The present invention provides a fused ring compound containing furan or a pharmaceutically acceptable salt thereof, a method for preparing same, a pharmaceutical composition comprising same, and a use thereof. The fused ring compound containing furan or a pharmaceutically acceptable salt thereof inhibits the activity of phosphatidylinositol 3-kinase (PI3K) and can therefore be used in a pharmaceutical composition for treating and preventing respiratory diseases, inflammatory diseases, proliferative diseases, cardiovascular diseases, or central nervous system diseases which occur due to the over-activation of PI3K.

摘要翻译： 本发明提供含有呋喃或其药学上可接受的盐的稠环化合物，其制备方法，包含其的药物组合物及其用途。 含有呋喃或其药学上可接受的盐的稠环化合物抑制磷脂酰肌醇3-激酶（PI3K）的活性，因此可用于治疗和预防呼吸系统疾病，炎性疾病，增殖性疾病，心血管疾病或中枢的药物组合物 由于PI3K的过度激活而发生的神经系统疾病。